Your browser doesn't support javascript.
loading
Adult-onset Still's disease: analysis of a monocentric cohort of patients.
Testa, D; Bilia, S; Tavoni, A G; Migliorini, P.
Affiliation
  • Testa D; Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Bilia S; Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Tavoni AG; Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Migliorini P; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Scand J Rheumatol ; 53(4): 263-268, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38695135
ABSTRACT

OBJECTIVE:

Adult-onset Still's disease (AOSD) is a multigenic autoinflammatory disease with a severe systemic involvement. Because of the rarity of the disease, most published cohorts are multicentric. The aim of this report is to describe a monocentric cohort of AOSD patients, reporting clinical features and response to therapy in a long follow-up.

METHOD:

Thirty-eight patients, attending the Clinical Immunology Unit and fulfilling Yamaguchi, Fautrel, or Daghor-Abbaci classification criteria for AOSD, were recruited for this study. In all patients, clinical and serological data were collected at diagnosis and every 6 months thereafter. The Pouchot score was calculated at every visit.

RESULTS:

Fever, arthromyalgia, and skin rash were the most frequent manifestations, followed by lymphadenopathy, sore throat, arthritis, splenomegaly, hepatic involvement, pleuropericarditis, and weight loss. As far as the disease course is concerned, 25% presented a monocyclic and 35% a polycyclic pattern, and 40% developed chronic articular involvement. Severe complications were observed at disease onset in 21% of the patients. All of the patients were treated with steroids; 74% also received conventional synthetic disease-modifying anti-rheumatic drugs (methotrexate in most cases) and 71% biological disease-modifying anti-rheumatic drugs (interleukin-1 inhibitors in most cases). Therapeutic switching for lack/loss of efficacy or adverse drug reactions was necessary in 66%.

CONCLUSION:

The analysis of this cohort confirms that AOSD is a complex, severe, and heterogeneous disease. However, despite long-term treatment and comorbidities, therapies are effective and well tolerated. The therapeutic armamentarium now available allows long-lasting remission with low immunosuppression to be achieved in most patients.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Methotrexate / Still's Disease, Adult-Onset / Antirheumatic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Scand J Rheumatol Year: 2024 Document type: Article Affiliation country: Italia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Methotrexate / Still's Disease, Adult-Onset / Antirheumatic Agents Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Scand J Rheumatol Year: 2024 Document type: Article Affiliation country: Italia